Lunac, Domainex join forces on anticoagulant discovery ‘urgent need’

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/shironosov)
(Image: Getty/shironosov)

Related tags: Coagulation, discovery services, assessment, Contract research organization

Domainex is set to support Lunac’s discovery project for anticoagulant therapies with reduced bleeding risk, following the developer’s novel target validation.

Drug discovery services provider, Domainex, entered a partnership agreement with Lunac Therapeutics, in an aim to support the latter discover anticoagulant therapies that have a reduced risk of bleeding compared to current therapies.

A spin-out of the University of Leeds, Lunac, has validated a protease target, activated ‘Factor XII’, that is implicated in the formation of pathological clots, but not the stemming of bleeding.

The company’s research has identified that individuals who lack this factor do not exhibit bleeding symptoms unlike those with a deficiency in any other coagulation factor.

Scientific founder of Lunac, Helen Philippou, said that the anticipated discovery answers an ‘urgent need’ for anticoagulant therapies with reduced bleeding risk, adding that targeting activated Factor XII may lead to differentiated therapies and a new treatment option for patients.

The partnership will see Domainex provide structure-guided medicinal chemistry and biochemical screening, as well as drug metabolism, safety and pharmacokinetic assessment of the potential candidates.

Upon discovery of the potential target inhibitor, the partners plan to advance the project efficiently into pre-clinical development and ultimately to clinical evaluation.

Lunac’s discovery project is backed by funding of £2.65m ($3.42m) raised during its Series A financing round, as well as of £3.14m ($4.05m) from the Innovate UK’s Biomedical Catalyst program.

Related news

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q² Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Related suppliers

Follow us


View more